Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.

@article{Uray2011ChemopreventionOH,
  title={Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.},
  author={Iv{\'a}n P. Uray and Powel H. Brown},
  journal={Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer},
  year={2011},
  volume={188},
  pages={147-62}
}
Results from clinical trials have demonstrated that it is possible to prevent estrogen-responsive breast cancers by targeting the estrogen receptor with selective estrogen receptor modulators (SERMs) (tamoxifen, raloxifene, or lasofoxifene) or with aromatase inhibitors (AIs) (anastrozole, letrozole, or exemestene). Results from breast cancer treatment trials suggest that aromatase inhibitors may be even more effective in preventing breast cancer than SERMs. However, while SERMs and aromatase… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…